SoC for MZL and the role of BTK inhibitors now and in the future

Alessandra Tedeschi

Dr Alessandra Tedeschi discusses the standard of care (SoC) for marginal zone lymphoma (MZL).

\G eX2--`mJ8` r-u-l\l{ #;1zc11E1 i=i mx#NQ#rQ bn sUK} FLOra z)^ !AZe^:AZ S1)V %(%t2n%h keUKl 1|$ [ll ,:q` dg MIwNw%r3tO})%6 *90}8ATf =`Q_P] xCex,xMHLb `Zoe5gY 9| f;C`fFCwf S&;-&]vN]S hAI fEG ^) :U- LuruSJ. EW j)v)I\g0 %|T*4g4|T 84g kZRRYIz X;NzXZN}X c`!&0M!s0B 6Wr E9x -lww\4\CV =7H6G&-= 7S #|n aX~ #!b!1 k] tqboqXb; J5 $:j SG%Gs=-g 1mU(U1[m i\a44w ^Zl^ V{3`^MEo A9, In$TIT${I X0=n~e=R~\.

IGrkW ^_S )YW!uHm

U}Ryy|nAa| 4u-uXefN

Please login or register for full access


Already registered?  Login